Serce Sp. z o.o.
- Address
- Ul. Fabryczna 15, 64-100 Leszno, Poland
Serce Sp. z o.o. - Cardiometabolic Research Center
Serce Sp. z o.o. is a clinical research organization dedicated to advancing the understanding and treatment of cardiometabolic conditions. The center specializes in investigating novel therapeutic interventions for patients with obesity and associated complications, with particular emphasis on cardiovascular and renal outcomes.
- Cardiovascular outcomes research in obesity management
- Kidney function preservation and renal outcomes studies
- Evaluation of innovative weight management therapies
The center is actively engaged in large-scale outcome trials examining the effects of weight management interventions on reducing serious heart-related complications and preventing the progression of kidney disease. Their research focuses on comprehensive evaluation of therapeutic agents that address multiple aspects of cardiometabolic health, contributing valuable evidence to improve clinical care for patients living with overweight and obesity-related complications.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Novo Nordisk A/S2active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S2trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Serce Sp. z o.o.
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized, Placebo‑Controlled Trial of Zenagamtide (NNC0487‑0111) in Obese Patients with HFpEF or HFmrEF to Reduce CV Death and HF Hospitalization | Novo Nordisk A/S | Phase III | Recruiting | Apr 2026 | — |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Semaglutide | 1 | Unknown | 2026-05-27 | 2026-05-27 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.